Skip to main content
. 2019 Mar 14;39(12):NP495–NP503. doi: 10.1093/asj/sjz067

Table 3.

Incidence and Duration of Adverse Events

Patients (n = 12)
Numbness, n (%) 12 (100)
 Duration, all treatments, mean ± SD, days 18.6 ± 5.7a
 Duration among patients who received 1 treatment, mean ± SD, days 25.5 ± 2.9
 Duration in first treatment, mean ± SD, days 20.8 ± 5.7
 Duration among patients who received ≥2 treatments, mean ± SD, days 16.8 ± 4.8
 Duration in subsequent treatments, mean ± SD, days 15.8 ± 4.3
Edema, n (%) 12 (100)
 Duration, all treatments, mean ± SD, days 6.0 ± 3.3b
 Duration among patients who received 1 treatment, mean ± SD, days 9.3 ± 4.6
 Duration in first treatment, mean ± SD, days 8.1 ± 3.2
 Duration among patients who received ≥2 treatments, mean ± SD, days 5.2 ± 2.4
 Duration in subsequent treatments, mean ± SD, days 3.6 ± 1.3
Tenderness, n (%) 11 (92)
 Duration, all treatments, mean ± SD, days 4.5 ± 2.4
 Duration among patients who received 1 treatment, mean ± SD, days 6.7 ± 2.9
 Duration in first treatment, mean ± SD, days 4.7 ± 2.9
 Duration among patients who received ≥2 treatments, mean ± SD, days 4.1 ± 2.1
 Duration in subsequent treatments, mean ± SD, days 3.7 ± 2.0
Bruising, n (%) 5 (42)c
 Duration, all treatments, mean, days 4.8
 Duration among patients who received 1 treatment, mean, days 4.0
 Duration in first treatment, mean, days 5.2
 Duration among patients who received ≥2 treatments, mean, days 5.3
 Duration in subsequent treatments, mean, days 3.0
Induration, n (%) 1 (8)d

SD, standard deviation. aDuration was unknown in 1 patient who received 1 treatment; duration was 18 days after the first treatment and of unknown duration after the second treatment in 1 patient. bDuration was unknown in 1 patient who received 1 treatment. cIn 1 patient, bruising occurred on the left side only during the first treatment; in 1 patient, bruising occurred only after the third of 4 treatments. dOccurred in 1 patient and lasted for 7 and 9 days after the first and second treatments, respectively.